Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

Air Transport Publications

home > pmps > winter 2002 > formulation integrated device systems for novel enhanced performance products

PUBLICATIONS

Pharmaceutical Manufacturing and Packing Sourcer Formulation Integrated Device Systems for Novel Enhanced Performance Products
The aim of developing formulation integrated device systems (FIDS) is to achieve enhanced performance from drugs, using technology that is aimed at solving specific biopharmaceutical, therapeutic, clinical or production problems. These patent-protected high performance systems are designed to provide better treatment outcomes and greater satisfaction for patients, whilst enabling new product development applications and enhanced Ôlife cycle managementÕ opportunities for pharmaceutical companies.
Read full article >>



Rate this article	You must be a member of the site to make a vote.	Average rating:	0

There are no comments in regards to this article.

Post a comment

Read all comments

By Professor John N Staniforth, Chief Scientific Officer at Vectura Ltd
Professor John N Staniforth PhD MRPharmS FZS CChem FRSC Churchill Fellow, is Chief Scientific Officer of Vectura, a pharmaceutical company specialising in novel pulmonary, oral and dermal technology and new product developments, based in the UK.

John has authored over 200 scientific publications in the area of pharmaceutical technology and is an Honorary Professor of the University of Bath. He is a Non-Executive Director of Penwest Pharmaceuticals Co Inc, New York, and a Founding Director of the drug delivery company, Phoqus Pharmaceuticals Ltd, UK.